Regeneron Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.: A Comprehensive Revenue Analysis

Regeneron vs. Taro: A Decade of Revenue Dynamics

__timestampRegeneron Pharmaceuticals, Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 20142819557000759285000
Thursday, January 1, 20154103728000862944000
Friday, January 1, 20164860427000950751000
Sunday, January 1, 20175872227000879387000
Monday, January 1, 20186710800000661913000
Tuesday, January 1, 20197863400000669893000
Wednesday, January 1, 20208497100000644769000
Friday, January 1, 202116071700000548970000
Saturday, January 1, 202212172900000561347000
Sunday, January 1, 202313117200000572952000
Monday, January 1, 202414202000000629182000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Pharmaceutical Giants: Regeneron and Taro

In the ever-evolving landscape of pharmaceuticals, Regeneron Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. have carved distinct paths over the past decade. From 2014 to 2023, Regeneron has seen a staggering growth in revenue, peaking in 2021 with a 470% increase from its 2014 figures. This growth trajectory underscores Regeneron's innovative prowess and market adaptability.

Conversely, Taro's revenue has experienced a more modest fluctuation, with a slight decline of around 25% from its 2016 peak. Despite this, Taro remains a steadfast player in the industry, maintaining a consistent presence.

The data for 2024 is incomplete, leaving room for speculation on future trends. As these companies continue to navigate the complexities of the pharmaceutical world, their financial journeys offer valuable insights into the industry's dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025